
SELLAS Life Sciences Group (NASDAQ:SLS) said its experimental cancer vaccine galinpepimut-S met the primary goal of improving overall survival in a Phase III trial involving patients with acute myeloid leukemia, or AML.
Median overall survival was 24 months for patients who received galinpepimut-S, known as GPS, compared with 14.7 months for those given investigator-selected best available treatment, President and CEO Angelos Stergiou said during a webcast. The result represented a 41% reduction in the risk of death, with a hazard ratio of 0.59 and a p-value of 0.035, he said.
The global REGAL trial enrolled 126 patients who had achieved a second or later complete remission, or complete remission with incomplete platelet recovery, and were ineligible or unable to undergo an allogeneic stem cell transplant. Patients were randomly assigned to receive GPS alone or a treatment selected by their physicians.
Trial results and safety
Stergiou said the control group received active treatment rather than a placebo. Physicians could select hypomethylating agents such as azacitidine or decitabine, venetoclax, or low-dose cytarabine, either alone or in combinations permitted by the trial protocol.
He said the control group’s median survival exceeded the approximately eight to 10 months historically observed in real-world evidence for patients in a second complete remission. GPS was administered as a single agent, while control-group physicians could select single drugs or combinations.
Treatment-related adverse events with GPS were predominantly mild to moderate, Stergiou said, with temporary injection-site reactions the most common. He said no new safety signals were identified and that the company would share a comprehensive safety analysis after completing its evaluation of the data.
Regulatory and pipeline plans
SELLAS plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy and prepare a biologics license application for GPS in the first half of 2027, Stergiou said. The company is also advancing manufacturing, regulatory and launch preparations.
The company is evaluating secondary endpoints, prespecified subgroups and immunologic data, and plans to present the full dataset at a medical conference and publish it in a peer-reviewed journal, he said.
GPS targets WT1, an antigen Stergiou said is overexpressed across approximately 20 tumor types. He said SELLAS and its collaborators have studied the therapy outside AML, including in mesothelioma, ovarian cancer and multiple myeloma, and believe it could have broader potential.
Stergiou also said SELLAS is advancing SLS009, a CDK9 inhibitor. The company expects to present additional Phase II data in relapsed or refractory AML at ASH 2026 and initial top-line results from a randomized Phase II trial in newly diagnosed AML later this year.
About SELLAS Life Sciences Group (NASDAQ:SLS)
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.
